Serum neurofilament light chain levels in MS: a promising biomarker of clinical and subclinical disease severity.

被引：0
|
作者：
Disanto, G. [1 ]
Barro, C. [2 ,3 ]
Giardiello, A. [1 ]
Gobbi, C. [1 ]
Zecca, C. [1 ]
Kuhle, J. [2 ,3 ]
机构：
[1] Neuroctr Southern Switzerland, Lugano, Switzerland
[2] Univ Hosp, Basel, Switzerland
[3] Univ Basel, Basel, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
基金：
新加坡国家研究基金会;
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1602
引用
收藏
页码：845 / 845
页数：1
相关论文
共 50 条
  • [41] Serum neurofilament light chain as a severity marker for spinocerebellar ataxia
    Shin, Hye-Rim
    Moon, Jangsup
    Lee, Woo-Jin
    Lee, Han Sang
    Kim, Eun Young
    Shin, Seoyi
    Lee, Soon-Tae
    Jung, Keun-Hwa
    Park, Kyung-Il
    Jung, Ki-Young
    Lee, Sang Kun
    Chu, Kon
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [42] Clinical and MRI correlates of CSF neurofilament light chain levels in relapsing and progressive MS
    Damasceno, Alfredo
    Dias-Carneiro, Rafael Paterno C.
    Moraes, Adriel Santos
    Boldrini, Vinicius O.
    Quintiliano, Raphael Patricio S.
    de Paula Galdino da Silva, Veronica Almeida
    Farias, Alessandro S.
    Brandao, Carlos Otavio
    Damasceno, Benito Pereira
    Barbosa dos Santos, Leonilda Maria
    Cendes, Fernando
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 30 : 149 - 153
  • [43] Towards optimized monitoring of serum neurofilament light chain in ms
    Uher, T.
    Kuhle, J.
    Bergsland, N.
    Krasensky, J.
    Javor, A.
    Srpova, B.
    Barro, C.
    Dwyer, M.
    Tyblova, M.
    Benkert, P.
    Leppert, D.
    Havrdova, E.
    Vaneckova, M.
    Zivadinov, R.
    Kalincik, T.
    Horakova, D.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 202 - 202
  • [44] Long term MS clinical outcomes predicted by baseline serum neurofilament light levels
    Abdoli, M.
    Thebault, S.
    Freedman, M. S.
    Fereshtehnejad, S. M.
    Tabard-Cossa, V.
    Tessier, D. R.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 506 - 507
  • [45] Serum neurofilament light chain levels are increased at the onset of PML in natalizumab treated MS patients
    Dalla Costa, G.
    Martinelli, V.
    Furlan, R.
    Finardi, A.
    Sangalli, F.
    Colombo, B.
    Moiola, L.
    Cinque, P.
    Kolb, E.
    Haghikia, A.
    Gold, R.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 368 - 369
  • [46] Serum neurofilament light chain levels are increased at the onset of PML in natalizumab treated MS patients
    Dalla Costa, Gloria
    Martinelli, Vittorio
    Finardi, Annamaria
    Sangalli, Francesca
    Colombo, Bruno
    Moiola, Lucia
    Cinque, Paola
    Kolb, Eva-Maria
    Haghikia, Aiden
    Gold, Ralf
    Furlan, Roberto
    Comi, Giancarlo
    NEUROLOGY, 2018, 90
  • [47] Neurofilament-Light, a Promising Biomarker: Analytical, Metrological and Clinical Challenges
    Coppens, Salome
    Lehmann, Sylvain
    Hopley, Christopher
    Hirtz, Christophe
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (14)
  • [48] Plasma neurofilament light as a promising biomarker in neuronal intranuclear inclusion disease
    Minglei Liu
    Yuru Zhu
    Yanpeng Yuan
    Yangyang Wang
    Xiaojing Liu
    Lanjun Li
    Yuan Gao
    Huimin Yan
    Ruoyu Liu
    Lin Cheng
    Jing Yuan
    Qingzhi Wang
    Shuo Li
    Yutao Liu
    Yanlin Wang
    Changhe Shi
    Yuming Xu
    Jing Yang
    Journal of Neurology, 2024, 271 : 2042 - 2052
  • [49] Plasma neurofilament light as a promising biomarker in neuronal intranuclear inclusion disease
    Liu, Minglei
    Zhu, Yuru
    Yuan, Yanpeng
    Wang, Yangyang
    Liu, Xiaojing
    Li, Lanjun
    Gao, Yuan
    Yan, Huimin
    Liu, Ruoyu
    Cheng, Lin
    Yuan, Jing
    Wang, Qingzhi
    Li, Shuo
    Liu, Yutao
    Wang, Yanlin
    Shi, Changhe
    Xu, Yuming
    Yang, Jing
    JOURNAL OF NEUROLOGY, 2024, 271 (04) : 2031 - 2041
  • [50] Serum neurofilament light chain as a biomarker for disease activity in paediatric neuroinflammatory conditions with and without myelitis
    Levine, Jesse
    Kannan, Varun
    Fisher, Kristen
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 304 - 304
12345